全文获取类型
收费全文 | 4172篇 |
免费 | 297篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 91篇 |
儿科学 | 281篇 |
妇产科学 | 150篇 |
基础医学 | 464篇 |
口腔科学 | 107篇 |
临床医学 | 457篇 |
内科学 | 742篇 |
皮肤病学 | 105篇 |
神经病学 | 345篇 |
特种医学 | 219篇 |
外科学 | 599篇 |
综合类 | 53篇 |
一般理论 | 1篇 |
预防医学 | 341篇 |
眼科学 | 101篇 |
药学 | 188篇 |
中国医学 | 1篇 |
肿瘤学 | 243篇 |
出版年
2024年 | 3篇 |
2023年 | 41篇 |
2022年 | 75篇 |
2021年 | 149篇 |
2020年 | 79篇 |
2019年 | 155篇 |
2018年 | 158篇 |
2017年 | 135篇 |
2016年 | 133篇 |
2015年 | 180篇 |
2014年 | 213篇 |
2013年 | 294篇 |
2012年 | 348篇 |
2011年 | 320篇 |
2010年 | 208篇 |
2009年 | 140篇 |
2008年 | 268篇 |
2007年 | 256篇 |
2006年 | 230篇 |
2005年 | 221篇 |
2004年 | 177篇 |
2003年 | 152篇 |
2002年 | 132篇 |
2001年 | 41篇 |
2000年 | 35篇 |
1999年 | 39篇 |
1998年 | 33篇 |
1997年 | 30篇 |
1996年 | 34篇 |
1995年 | 22篇 |
1994年 | 13篇 |
1993年 | 15篇 |
1992年 | 12篇 |
1991年 | 11篇 |
1990年 | 10篇 |
1989年 | 10篇 |
1988年 | 14篇 |
1987年 | 9篇 |
1986年 | 11篇 |
1985年 | 9篇 |
1984年 | 11篇 |
1983年 | 3篇 |
1982年 | 7篇 |
1981年 | 7篇 |
1980年 | 7篇 |
1979年 | 7篇 |
1978年 | 5篇 |
1977年 | 8篇 |
1976年 | 7篇 |
1948年 | 2篇 |
排序方式: 共有4488条查询结果,搜索用时 15 毫秒
21.
22.
Kara IG Sarioğlu A 《Burns : journal of the International Society for Burn Injuries》1999,25(7):663-665
Thermal injury of the genitalia usually occurs as part of larger body surface burns. The most common sequelae of burns of the penoscrotal region are contractures of penile shaft, but we did not encounter any reported cases in English Literature with cryptorchidism as a sequel of burn injury. A 7 year old boy with cryptorchidism as a component of extensive perineal and inguinal burn deformity is reported to indicate the role of burn injury in cryptorchidism. Cryptorchidism as a component of perineal burn injury may be caused by the attachment of the cremaster muscle or fascia to the abdominal wall during the process of wound healing. As healing process of wounds on inguinal region by contraction may cause testis entrapment and cryptorchidism, a careful genital examination bears a great importance in inguinal burn deformities in order not to miss any trapped testis and replace it as early as possible before degenerative changes begin. 相似文献
23.
Hayrettin Kara Sabahattin Aydin M. Yucel Agargun Oner Odabas Yuksel Yilmaz 《The Journal of urology》1996,156(5):1631-1632
Purpose
The efficacy of the selective serotonin re-uptake inhibitor fluoxetine in the treatment of premature ejaculation was examined.Materials and Methods
The study comprised 17 patients with premature ejaculation who presented to the urology clinic of our medical school. In this double-blind study the patients were randomized into treatment groups receiving 20 mg. fluoxetine daily for 1 week and 40 mg. daily afterward (group 1) or 1 capsule placebo daily for 1 week and 2 capsules daily afterward (group 2). The groups were evaluated according to the latent period of intravaginal ejaculation.Results
The latent period of intravaginal ejaculation in group 1 was significantly longer than that in group 2. Nausea, headache and insomnia were reported side effects.Conclusions
Fluoxetine may be regarded as a safe and effective alternative in the treatment of premature ejaculation. 相似文献24.
Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine 总被引:1,自引:0,他引:1
güler Kanra Simonetta Viviani Kadriye Yurdakök Elif Özmert Alessandra Anemona SongüL Yalçn Okan Demiralp Nihan Bilgili Ates Kara Ali BüLent Cengiz Belgin Mutlu Alexandra Baldini Elisa Marchetti Audino Podda 《Pediatrics international》2003,45(3):314-318
OBJECTIVE: The present study was carried out to evaluate the safety and immunogenicity of the Haemophilus influenzae type b-CRM197 (Hib-CRM197) conjugate vaccine in relation to the change of adjuvant from aluminum hydroxide to aluminum phosphate (AlPO4). METHODS: The present study was a clinical phase II, observer-blind, randomized, multicenter, controlled study. Subjects were healthy infants aged 6-12 weeks, eligible for expanded program of immunization (EPI) routine vaccination and admitted to Hacettepe University Department of Social Pediatrics and Gülveren Health Center, Ankara. A total of 520 healthy infants were randomized in a 2:2:1 ratio to receive at either Chiron Hib/AlPO4 vaccine or VaxemHib (aluminum hydroxide adjuvant) vaccine or HibTiter (no adjuvant). Vaccines were administered simultaneously with routine diphtheria, tetanus and pertussis (DTaP) and oral polio vaccine (OPV) vaccines at 2, 4 and 6 months of age. Blood samples for anti-plain polysaccharide (PRP) antibody measurement were collected before the first vaccination and 1 month after the last vaccination. After each vaccination parents filled out a diary for 7 days. RESULTS: Out of 520 subjects enrolled, 514 received three doses and were included for safety analysis. Local and systemic reactions occurred with low and similar frequencies in all groups. Only erythema was more common in Chiron Hib/AlPO4 vaccine (19, 10, 11% in Chiron Hib/AlPO4, VaxemHib and HibTiter, respectively, P < 0.05). Nine serious adverse events were reported in seven cases of which none were related to vaccines. A total of 504 subjects were included in the immunogenicity analysis. The three vaccines were highly immunogenic and equivalent in terms of percentage of acquisition of long-term protective levels. The anti-PRP geometric mean titers were 9.9, 8.3 and 5.14 micro g/mL, respectively (P < 0.05). CONCLUSIONS: The use of aluminum compounds adjuvants in Hib-CRM197 conjugate vaccines does not impact the safety profile, while it does increase the magnitude of anti-PRP antibody titers. 相似文献
25.
Phase II trial of gefitinib in recurrent glioblastoma. 总被引:13,自引:0,他引:13
Jeremy N Rich David A Reardon Terry Peery Jeannette M Dowell Jennifer A Quinn Kara L Penne Carol J Wikstrand Lauren B Van Duyn Janet E Dancey Roger E McLendon James C Kao Timothy T Stenzel B K Ahmed Rasheed Sandra E Tourt-Uhlig James E Herndon James J Vredenburgh John H Sampson Allan H Friedman Darell D Bigner Henry S Friedman 《Journal of clinical oncology》2004,22(1):133-142
PURPOSE: To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. PATIENTS AND METHODS: This was an open-label, single-center phase II trial. Fifty-seven patients with first recurrence of a glioblastoma who were previously treated with surgical resection, radiation, and usually chemotherapy underwent an open biopsy or resection at evaluation for confirmation of tumor recurrence. Each patient initially received 500 mg of gefitinib orally once daily; dose escalation to 750 mg then 1,000 mg, if a patient received enzyme-inducing antiepileptic drugs or dexamethasone, was allowed within each patient. RESULTS: Although no objective tumor responses were seen among the 53 assessable patients, only 21% of patients (11 of 53 patients) had measurable disease at treatment initiation. Seventeen percent of patients (nine of 53 patients) underwent at least six 4-week cycles, and the 6-month event-free survival (EFS) was 13% (seven of 53 patients). The median EFS time was 8.1 weeks, and the median overall survival (OS) time from treatment initiation was 39.4 weeks. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Drug-related toxicities were more frequent at higher doses. Withdrawal caused by drug-related adverse events occurred in 6% of patients (three of 53 patients). Although the presence of diarrhea positively predicted favorable OS from treatment initiation, epidermal growth factor receptor expression did not correlate with either EFS or OS. CONCLUSION: Gefitinib is well tolerated and has activity in patients with recurrent glioblastoma. Further study of this agent at higher doses is warranted. 相似文献
26.
Primary nephrotic syndrome during childhood in Turkey 总被引:3,自引:0,他引:3
Nuray Özkaya Nilgün Çakar Mesiha Ekim Nazli Kara Nermin Akkök Fatos Yalçinkaya 《Pediatrics international》2004,46(4):436-438
BACKGROUND: Minimal change nephrotic syndrome (MCNS) is the most common cause of primary nephrotic syndrome (NS) during childhood. However, recent studies from different countries have reported an increasing incidence of focal segmental glomerulosclerosis (FSGS) in children. METHODS: This is a retrospective study in which 392 Turkish children who were diagnosed with NS during the last 10 years and were followed for at least 2 years, were evaluated. Mean age of the study group was 4.6 +/- 3.4 years (range 0.9-16 years) and 232 were male and 160 were female. RESULTS: In total, 280 patients were diagnosed as MCNS with their initial presentations, laboratory features, and clinical course. Kidney biopsy was performed in the remaining 112 children according to current recommendations. The results showed that membranoproliferative glomerulonephritis (MPGN) was the most common histopathologic diagnosis, 38 (34%) of the 112 patients were found to have MPGN. The number diagnosed as FSGS was 26 (23%). A significant difference was found between the age groups for both MPGN and FSGS, the former being more common in children >6 years of age and the latter more frequent in children =6 years. MCNS was found in only 19% of all biopsies performed and the total incidence of MCNS (presumptive + biopsy proven) was 76%. There was no significant difference between the incidence of different histopathological subtypes before and after 1995. CONCLUSION: Minimal change nephrotic syndrome is still the most common primary NS in childhood and MPGN is found to be the most common histopathologic subtype in the present patient population who underwent biopsy. 相似文献
27.
Peter D Cole Richard A Drachtman Angela K Smith Sarah Cate Richard A Larson Douglas S Hawkins John Holcenberg Kara Kelly Barton A Kamen 《Clinical cancer research》2005,11(22):8089-8096
PURPOSE: To determine the antileukemic activity of weekly oral aminopterin in patients with refractory acute leukemia; to describe the pharmacodynamic properties of aminopterin; and to contrast the intracellular metabolism of aminopterin and methotrexate by patients' blasts in vitro. EXPERIMENTAL DESIGN: Forty-six patients were enrolled in three strata: children with acute lymphoblastic leukemia (ALL), adults with ALL, and patients with acute myeloid leukemia (AML). Aminopterin was given weekly, in two doses of 2 mg/m(2), 12 hours apart. Limited sampling pharmacokinetic analysis was done during the first week of therapy. Accumulation of [(3)H]aminopterin and [(3)H]methotrexate by leukemic blasts was studied in vitro. RESULTS: Six of 22 children with ALL (27%; 95% confidence interval, 8-47%) had clinically significant responses. None of those with AML and only two of 11 adults with ALL had responses meeting protocol definitions, although peripheral blast counts tended to decrease with therapy in all groups. Mucosal toxicity was minimal, even with limited use of leucovorin rescue. Complete bioavailability of aminopterin was confirmed, with a mean area under the curve of 0.52 +/- 0.03 micromol hour/L after oral dosing. No relationship between aminopterin pharmacokinetics and response was seen. In vitro, aminopterin showed more consistent metabolism by leukemic blasts to polyglutamates than methotrexate. Lineage-specific differences in the pattern of intracellular antifolylpolyglutamates were observed. CONCLUSIONS: Weekly oral aminopterin has significant activity among children with refractory ALL. With greater cellular accumulation and metabolism, more reliable bioavailability than methotrexate, and tolerable toxicity at this dose and schedule, aminopterin deserves further study as a potent alternative to methotrexate. 相似文献
28.
Complications from improperly placed biliary stents are not uncommon. Free loose wires from the ends of an uncovered stent can irritate and damage adjacent mucosal surfaces. Effective management can be achieved via percutaneous placement of a second stent to alter the orientation of the original stent. 相似文献
29.
30.
Outcome of children and adolescents with Down syndrome treated on Dana‐Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00–001 and 05‐001
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Uma H. Athale Maneka Puligandla Kristen E. Stevenson Barbara Asselin Luis A. Clavell Peter D. Cole Kara M. Kelly Caroline Laverdiere Jean‐Marie Leclerc Bruno Michon Marshall A. Schorin Maria Luisa Sulis Jennifer J. G. Welch Marian H. Harris Donna S. Neuberg Stephen E. Sallan Lewis B. Silverman 《Pediatric blood & cancer》2018,65(10)